Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217158 · ClinicalTrials.gov registry record
Role of ROS and cAMP-PKA Biomarkers in ADPKD
A clinical trial of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07217158: Active study of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
NCT07217158 is a study of Autosomal Dominant Polycystic Kidney Disease that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 150-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217158, a study of Autosomal Dominant Polycystic Kidney Disease, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
Primary Outcome
TKV determined by MRI
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2027-06-30 |
What the registry record for NCT07217158 still lists
NCT07217158 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 150-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07217158 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07217158 about?
NCT07217158 is a clinical study titled "Role of ROS and cAMP-PKA Biomarkers in ADPKD". The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
What is the current status of trial NCT07217158?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT07217158 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.
Who is sponsoring clinical trial NCT07217158?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217158 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217158's enrollment target sits among peer trials
100 4th of 9 higher than 6 of 9 other Autosomal Dominant Polycystic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autosomal Dominant Polycystic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING
-
NOX4 and Related Biomarkers in ADPKD
RECRUITING
-
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING · Phase 2
-
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
RECRUITING · Phase 1
-
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
ACTIVE NOT RECRUITING
-
Intrarenal Microvasculature in ADPKD
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI